Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 Effect on Metformin PK in Healthy Subjects
NCT06654960Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS9531 in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Area under the concentration versus time curve from dosing time to tau at 3.5 days. Started Nov 2024; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06654960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654960.